These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
184 related articles for article (PubMed ID: 36739915)
1. BET proteins: Biological functions and therapeutic interventions. Guo J; Zheng Q; Peng Y Pharmacol Ther; 2023 Mar; 243():108354. PubMed ID: 36739915 [TBL] [Abstract][Full Text] [Related]
2. BET Bromodomain Inhibitors: Novel Design Strategies and Therapeutic Applications. To KKW; Xing E; Larue RC; Li PK Molecules; 2023 Mar; 28(7):. PubMed ID: 37049806 [TBL] [Abstract][Full Text] [Related]
3. Systematic analysis of the BET family in adrenocortical carcinoma: The expression, prognosis, gene regulation network, and regulation targets. Situ Y; Liang Q; Zeng Z; Chen J; Shao Z; Xu Q; Lu X; Cui Y; Zhang J; Lu L; Deng L Front Endocrinol (Lausanne); 2023; 14():1089531. PubMed ID: 36793283 [TBL] [Abstract][Full Text] [Related]
4. Small-Molecule Targeting of BET Proteins in Cancer. French CA Adv Cancer Res; 2016; 131():21-58. PubMed ID: 27451123 [TBL] [Abstract][Full Text] [Related]
5. The Bromodomain and Extra-Terminal Domain (BET) Family: Functional Anatomy of BET Paralogous Proteins. Taniguchi Y Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27827996 [TBL] [Abstract][Full Text] [Related]
6. BRD4 bimodal binding at promoters and drug-induced displacement at Pol II pause sites associates with I-BET sensitivity. Khoueiry P; Ward Gahlawat A; Petretich M; Michon AM; Simola D; Lam E; Furlong EE; Benes V; Dawson MA; Prinjha RK; Drewes G; Grandi P Epigenetics Chromatin; 2019 Jul; 12(1):39. PubMed ID: 31266503 [TBL] [Abstract][Full Text] [Related]
7. Dual-target inhibitors of bromodomain and extra-terminal proteins in cancer: A review from medicinal chemistry perspectives. Feng L; Wang G; Chen Y; He G; Liu B; Liu J; Chiang CM; Ouyang L Med Res Rev; 2022 Mar; 42(2):710-743. PubMed ID: 34633088 [TBL] [Abstract][Full Text] [Related]
8. The Functions of BET Proteins in Gene Transcription of Biology and Diseases. Cheung KL; Kim C; Zhou MM Front Mol Biosci; 2021; 8():728777. PubMed ID: 34540900 [TBL] [Abstract][Full Text] [Related]
9. Discovery and characterization of bromodomain 2-specific inhibitors of BRDT. Yu Z; Ku AF; Anglin JL; Sharma R; Ucisik MN; Faver JC; Li F; Nyshadham P; Simmons N; Sharma KL; Nagarajan S; Riehle K; Kaur G; Sankaran B; Storl-Desmond M; Palmer SS; Young DW; Kim C; Matzuk MM Proc Natl Acad Sci U S A; 2021 Mar; 118(9):. PubMed ID: 33637650 [TBL] [Abstract][Full Text] [Related]
10. Prostate cancer-associated SPOP mutations confer resistance to BET inhibitors through stabilization of BRD4. Dai X; Gan W; Li X; Wang S; Zhang W; Huang L; Liu S; Zhong Q; Guo J; Zhang J; Chen T; Shimizu K; Beca F; Blattner M; Vasudevan D; Buckley DL; Qi J; Buser L; Liu P; Inuzuka H; Beck AH; Wang L; Wild PJ; Garraway LA; Rubin MA; Barbieri CE; Wong KK; Muthuswamy SK; Huang J; Chen Y; Bradner JE; Wei W Nat Med; 2017 Sep; 23(9):1063-1071. PubMed ID: 28805820 [TBL] [Abstract][Full Text] [Related]
14. Inhibition of BET bromodomains as a therapeutic strategy for cancer drug discovery. Fu LL; Tian M; Li X; Li JJ; Huang J; Ouyang L; Zhang Y; Liu B Oncotarget; 2015 Mar; 6(8):5501-16. PubMed ID: 25849938 [TBL] [Abstract][Full Text] [Related]
15. Discovery of novel small molecule induced selective degradation of the bromodomain and extra-terminal (BET) bromodomain protein BRD4 and BRD2 with cellular potencies. Jiang F; Wei Q; Li H; Li H; Cui Y; Ma Y; Chen H; Cao P; Lu T; Chen Y Bioorg Med Chem; 2020 Jan; 28(1):115181. PubMed ID: 31767403 [TBL] [Abstract][Full Text] [Related]
16. Bromodomain and extra-terminal domain bromodomain inhibition prevents synovial inflammation via blocking IκB kinase-dependent NF-κB activation in rheumatoid fibroblast-like synoviocytes. Xiao Y; Liang L; Huang M; Qiu Q; Zeng S; Shi M; Zou Y; Ye Y; Yang X; Xu H Rheumatology (Oxford); 2016 Jan; 55(1):173-84. PubMed ID: 26324948 [TBL] [Abstract][Full Text] [Related]
17. Targetable BET proteins- and E2F1-dependent transcriptional program maintains the malignancy of glioblastoma. Xu L; Chen Y; Mayakonda A; Koh L; Chong YK; Buckley DL; Sandanaraj E; Lim SW; Lin RY; Ke XY; Huang ML; Chen J; Sun W; Wang LZ; Goh BC; Dinh HQ; Kappei D; Winter GE; Ding LW; Ang BT; Berman BP; Bradner JE; Tang C; Koeffler HP Proc Natl Acad Sci U S A; 2018 May; 115(22):E5086-E5095. PubMed ID: 29764999 [TBL] [Abstract][Full Text] [Related]
18. Inhibitors of bromodomain and extra-terminal proteins for treating multiple human diseases. Kulikowski E; Rakai BD; Wong NCW Med Res Rev; 2021 Jan; 41(1):223-245. PubMed ID: 32926459 [TBL] [Abstract][Full Text] [Related]
19. BET bromodomain proteins are required for glioblastoma cell proliferation. Pastori C; Daniel M; Penas C; Volmar CH; Johnstone AL; Brothers SP; Graham RM; Allen B; Sarkaria JN; Komotar RJ; Wahlestedt C; Ayad NG Epigenetics; 2014 Apr; 9(4):611-20. PubMed ID: 24496381 [TBL] [Abstract][Full Text] [Related]
20. Discovery of Tetrahydroquinoxalines as Bromodomain and Extra-Terminal Domain (BET) Inhibitors with Selectivity for the Second Bromodomain. Law RP; Atkinson SJ; Bamborough P; Chung CW; Demont EH; Gordon LJ; Lindon M; Prinjha RK; Watson AJB; Hirst DJ J Med Chem; 2018 May; 61(10):4317-4334. PubMed ID: 29656650 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]